Premenstrual dysphoric disorder: A review for the treating practitioner

Cleveland Clinic Journal of Medicine

Volumn 71, Issue 4, 2004, Pages 303-321

  Kaur, Gurjit ^a   Gonsalves, Lilian ^a   Thacker, Holly L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BROMOCRIPTINE MESILATE; BUSPIRONE; CALCIUM; CITALOPRAM; CLOMIPRAMINE; DANAZOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; FLUOXETINE; GONADORELIN AGONIST; IBUPROFEN; LEUPRORELIN; MAGNESIUM; MECLOFENAMATE SODIUM; MECLOFENAMIC ACID; NAPROXEN; NEUROTRANSMITTER; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PAROXETINE; PROGESTERONE; PYRIDOXINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPIRONOLACTONE; UNINDEXED DRUG; VENLAFAXINE;

ACNE; ACUPRESSURE; ACUPUNCTURE; ALTERNATIVE MEDICINE; AMENORRHEA; BEHAVIOR DISORDER; BEHAVIOR MODIFICATION; BODY WEIGHT DISORDER; CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DRUG COST; DYSPHORIA; FATIGUE; FEMALE; FEMALE SEXUAL DYSFUNCTION; HEADACHE; HOMEOPATHY; HORMONE RESPONSE; HOT FLUSH; HUMAN; HYPERKALEMIA; INSOMNIA; IRRITABILITY; LETHARGY; LIFESTYLE; MANIPULATIVE MEDICINE; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENTAL INSTABILITY; MYALGIA; NAUSEA; NERVOUSNESS; OSTEOPOROSIS; PREMENSTRUAL SYNDROME; PSYCHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SOCIAL DISABILITY; SYMPTOMATOLOGY; VAGINAL DRYNESS; WEIGHT GAIN;

EID: 16544363826     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.71.4.303     Document Type: Review

References (111)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC, American Psychiatric Association; 1994.
2. Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990; 147:1634-1636.
3. Freeman EW, Rickels K, Schweizer E, Ting T. Relationships between age and symptom severity among women seeking medical treatment for premenstrual symptoms. Psychol Med 1995; 25:309-315.
4. Steiner M, Born L. Diagnosis and treatment of premenstrual dysphoric disorder: an update. Int Clin Psychopharmacol 2000; 15(suppl 3):S5-S17.
5. Pearlstein T, Stone AB. Premenstrual syndrome. Psychiatr Clin North Am 1998; 21:577-590.
6. Praschak-Rieder N, Willeit M, Neumeister A. et al. Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder. J Affect Disord 2001; 63:239-242.
7. Condon JT. The premenstrual syndrome: a twin study. Br J Psychiatry 1993; 162:481-486.
8. Kendler KS, Karkowski LM, Corey LA, Neale MC. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 1998; 155:1234-1240.
9. Frackiewicz EJ, Shiovitz TM. Evaluation and management of premenstrual syndrome and premenstrual dysphoric disorder. J Am Pharm Assoc (Wash) 2001; 41:437-447.
10. Merikangas KR, Foeldenyi M, Angst J. The Zurich Study. XIX Patterns of menstrual disturbances in the community: results of the Zurich Cohort Study. Eur Arch Psychiatry Clin Neurosci 1993; 243:23-32.
11. Severino SK, Moline ML. Premenstrual Syndrome: A Clinician's Guide. New York: Guilford Press; 1989.
12. Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999;8:122-128.
13. Hargrove JT, Abraham GE. The incidence of premenstrual tension in a gynecologic clinic. J Reprod Med 1982; 27:721-724.
14. Muse KN, Cetel NS, Futterman LA, Yen SC. The premenstrual syndrome. Effects of "medical ovariectomy." N Engl J Med 1984; 311:1345-1349.
15. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998; 338:209-216.
16. Rapkin AJ, Edelmuth E, Chang LC, Reading AE, McGuire MT, Su TP. Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol 1987; 70:533-537.
17. Taylor DL, Mathew RJ, Ho BT, Weinman ML. Serotonin levels and platelet uptake during premenstrual tension. Neuropsychobiology 1984; 12:16-18.
18. Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 1994; 32:37-44.
19. Dimmock PW, Wyatt KM, Jones PW, O'Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000; 356:1131-1136.
20. Finfgeld DL. Selective serotonin reuptake inhibitors and treatment of premenstrual dysphoric disorder. Perspect Psychiatr Care 2002; 38:50-60.
21. Steiner M, Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 2000; 61(suppl 12):17-21.
22. Sundstrom I, Backstrom T, Wang M, Olsson T, Seippel L, Bixo M. Premenstrual syndrome, neuroactive steroids and the brain. Gynecol Endocrinol 1999; 13:206-220.
23. Chuong CJ, Coulam CB, Kao PC, Bergstralh EJ, Go VL. Neuropeptide levels in premenstrual syndrome. Fertil Steril 1985; 44:760-765.
24. Chuong CJ, Hsi BP, Gibbons WE. Periovulatory beta-endorphin levels in premenstrual syndrome. Obstet Gynecol 1994; 83:755-760.
25. Giannini AJ, Martin DM, Turner CE. Beta-endorphin decline in late luteal phase dysphoric disorder. Int J Psychiatry Med 1990; 20:279-284.
26. Chuong CJ, Dawson EB, Smith ER. Vitamin A levels in premenstrual syndrome. Fertil Steril 1990; 54:643-647.
27. Chuong CJ, Dawson EB, Smith ER. Vitamin E levels in premenstrual syndrome. Am J Obstet Gynecol 1990; 163:1591-1595.
28. Kleijnen J, Ter Riet G, Knipschild P. Vitamin B6 in the treatment of the premenstrual syndrome - a review. Br J Obstet Gynaecol 1990; 97:847-852.
29. Wyatt KM, Dimmock PW, Jones PW, Shaughn O'Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. Br Med J 1999; 318:1375-1381.
30. Sherwood RA, Rocks BF, Stewart A, Saxton RS. Magnesium and the premenstrual syndrome. Ann Clin Biochem 1986; 23:667-670.
31. Facchinetti F, Borella P, Fioroni L, et al. Reduction of monocyte's magnesium in patients affected by premenstrual syndrome. J Psychosom Obstet Gynaecol 1990;11:221.
32. Rosenstein DL, Elin RJ, Hosseini JM, Grover G, Rubinow DR. Magnesium measures across the menstrual cycle in premenstrual syndrome. Biol Psychiatry 1994; 35:557-561.
33. Posaci C, Erten O, Uren A, Acar B. Plasma copper, zinc and magnesium levels in patients with premenstrual tension syndrome. Acta Obstet Gynecol Scand 1994; 73:452-455.
34. Okey R, Stewart J, Greenwood M. Studies in the metabolism of women. IV. The calcium and inorganic phosphorous in the blood of normal women at the various stages of the monthly cycle. J Biol Chem 1930; 87:91-102.
35. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998; 179:444-452.
36. Mortola JF, Girton L, Beck L, Yen SS. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol 1990; 76:302-307.
37. Moos RH. The development of a menstrual distress questionnaire. Psychosom Med 1968; 30:853-867.
38. Endicott J, Halbreich U. Retrospective report of premenstrual depressive changes: factors affecting confirmation by daily ratings. Psychopharmacol Bull 1982; 18:109-112.
39. Reid RL. Premenstrual syndrome. Curr Probl Obstet Gynecol Fertil 1985; 8:1.
40. Steiner M. Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management. J Psychiatry Neurosci 2000; 25:459-468.
41. Steiner M, Streiner DL, Steinberg S, et al. The measurement of premenstrual mood symptoms. J Affect Discord 1999; 53:269-273.
42. Wurtman JJ. Carbohydrate craving. Relationship between carbohydrate intake and disorders of mood. Drugs 1990; 39(suppl 3):49-52.
43. Sayegh R, Schiff I, Wurtman J, Spiers P, McDermott J, Wurtman R. The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet Gynecol 1995; 86:520-528.
44. Budoff PW. The use of prostaglandin inhibitors for the premenstrual syndrome. J Reprod Med 1983; 28:469-478.
45. Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int Clin Psychopharmacol 1999; 14(suppl 2):S27-S33.
46. Endicott J, Amsterdam J, Eriksson E, et al. Is premenstrual dysphoric disorder a distinct clinical entity? J Womens Health Gend Based Med 1999; 8:663-679.
47. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998; 59:76-80.
48. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998; 18:390-398.
49. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997; 58:399-402.
50. Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002; 100:1219-1229.
51. Cohen LS, Miner C, Brown EW, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002; 100:435-444.
52. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995; 332:1529-1534.
53. Miner C, Brown E, McCray S, Gonzales J, Wohlreich M. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002; 24:417-433.
54. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997; 278:983-988.
55. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995; 12:167-176.
56. Pearlstein T. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard? Drugs 2002; 62:1869-1885.
57. Guidotti A, Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability? Biol Psychiatry 1998; 44:865-873.
58. Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A 1999; 96:13512-13517.
59. Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPherson M, Upton GV. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001; 98:737-744.
60. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 1993; 9:133-145.
61. Sundblad C, Modigh K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 1992; 85:39-47.
62. Eriksson E, Lisjo P, Sundblad C, Andersson K, Andersch B, Modigh K. Effect of clomipramine on premenstrual syndrome. Acta Psychiatr Scand 1990; 81:87-88.
63. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry 1990; 47:270-275.
64. Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 1987; 70:37-43.
65. Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome. Lancet 1989; 1:777.
66. Brown CS, Ling FW, Farmer RG, et al. Buspirone in the treatment of premenstrual syndrome. Drug Ther 1990; 20:S112-S121.
67. Hazum E, Cuatrecasas P, Marian J, Conn PM. Receptor-mediated internalization of fluorescent gonadotropin-releasing hormone by pituitary gonadotropes. Proc Natl Acad Sci U S A 1980; 77:6692-6695.
68. American College of Obstetricians and Gynecologists. Premenstrual Syndrome: Clinical Management Guidelines for Obstetrician-Gynecologists. ACOG Practice Bulletin 2000; 15:1-9.
69. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1991; 72:252A-252F.
70. Dmowski WP. Endocrine properties and clinical application of danazol. Fertil Steril 1979; 31:237-251.
71. Andersch B. Bromocriptine and premenstrual symptoms: a survey of double blind trials. Obstet Gynecol Surv 1983; 38:643-646.
72. Eisner CW, Buster JE, Schindler RA, Nessim SA, Abraham GE. Bromocriptine in the treatment of premenstrual tension syndrome. Obstet Gynecol 1980; 56:723-726.
73. Wang M, Hammarback S, Lindhe BA, Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995; 74:803-808.
74. Burnet RB, Radden HS, Easterbrook EG, McKinnon RA. Premenstrual syndrome and spironolactone. Aust N Z J Obstet Gynaecol 1991; 31:366-368.
75. O'Brien PM, Craven D, Selby C, Symonds EM. Treatment of premenstrual syndrome by spironolactone. Br J Obstet Gynaecol 1979; 86:142-147.
76. Backstrom T, Hansson-Malmstrom Y, Lindhe BA, Cavalli-Bjorkman B, Nordenstrom S. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 1992; 46:253-268.
77. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992; 36:257-266.
78. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10:561-569.
79. Dalton K. The Premenstrual Syndrome and Progesterone Therapy. 2nd ed. Chicago, IL: Year Book Medical Publisher; 1984.
80. Dennerstein L, Spencer-Gardner C, Gotts G, Brown JB, Smith MA, Burrows GD. Progesterone and the premenstrual syndrome: a double blind crossover trial. BMJ 1985; 290:1617-1621.
81. Wyatt K, Dimmock P, Jones P, Obhrai M, O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001; 323:776-780.
82. Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 1990; 162:105-109.
83. Casson P, Hahn PM, Van Vugt DA, Reid RL. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 1990; 162:99-105.
84. Institute of Medicine. Dietary reference intakes: Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academy Press; 1997.
85. Facchinetti F, Borella P, Sances G, Fioroni L, Nappi RE, Genazzani AR. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol 1991; 78:177-181.
86. Walker AF, De Souza MC, Vickers MF, Abeyasekera S, Collins ML, Trinca LA. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health 1998; 7:1157-1165.
87. Institute of Medicine. Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic acid, Biotin, and Choline. Washington, DC: National Academy Press; 1998.
88. London RS, Murphy L, Kitlowski KE, Reynolds MA. Efficacy of alphatocopherol in the treatment of the premenstrual syndrome. J Reprod Med 1987; 32:400-404.
89. Penland JG, Johnson PE. Dietary calcium and manganese effects on menstrual cycle symptoms. Am J Obstet Gynecol 1993; 168:1417-1423.
90. Daugherty JE. Treatment strategies for premenstrual syndrome. Am Fam Physician 1998; 58:183-192, 197-198.
91. Harrison WM, Endicott J, Rabkin JG, Nee J. Treatment of premenstrual dysphoric changes: clinical outcome and methodological implications. Psychopharmacol Bull 1984; 20:118-122.
92. Johnson SR. Premenstrual syndrome therapy. Clin Obstet Gynecol 1998; 41:405-421.
93. Collins A, Cerin A, Coleman G, Landgren BM. Essential fatty acids in the treatment of premenstrual syndrome. Obstet Gynecol 1993; 81:93-98.
94. Khoo SK, Munro C, Battistutta D. Evening primrose oil and treatment of premenstrual syndrome. Med J Aust 1990; 153:189-192.
95. Foster S, Tyler V. Tyler's Honest Herbal. 4th ed. New York, NY: Haworth Press; 1999.
96. Sliutz G, Speiser P, Schultz AM, Spona J, Zeillinger R. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Horm Metab Res 1993; 25:253-255.
97. Schellenberg R. Treatment for the premenstrual syndrome with Agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 2001; 322:134-137.
98. Blumenthal M, Busse W, Goldberg A, et al. The complete German Commission E monographs. Therapeutic Guide to Herbal Medicines. Austin, TX: American Botanical Council; 1998.
99. Problems with dietary supplements: kava. Med Lett Drugs Ther 2002; 44:84-86.
100. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996; 125:940-941.
101. Stevinson C, Ernst E. A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome. BJOG 2000; 107:870-876.
102. Habek D, Habek JC, Barbir A. Using acupuncture to treat premenstrual syndrome. Arch Gynecol Obstet 2002; 267:23-26.
103. Van Zak DB. Biofeedback treatments for premenstrual and premenstrual affective syndromes. Int J Psychosom 1994; 41:53-60.
104. Chapman E, Angelica J, Spitalny G, et al. Results of a study of the homeopathic treatment of PMS. J Am Inst Homeopath 1994; 87:14-21.
105. Katz T. Homoeopathic treatment of premenstrual symptoms. Complement Ther Nurs Midwifery 1995; 1:133-137.
106. Walsh MJ, Polus BI. A randomized, placebo-controlled clinical trial on the efficacy of chiropractic therapy on premenstrual syndrome. J Manipulative Physiol Ther 1999; 22:582-585.
107. Hernandez-Reif M, Martinez A, Field T, Quintero O, Hart S, Burman I. Premenstrual symptoms are relieved by massage therapy. J Psychosom Obstet Gynaecol 2000; 21:9-15.
108. Oleson T, Flocco W. Randomized controlled study of premenstrual symptoms treated with ear, hand, and foot reflexology. Obstet Gynecol 1993; 82:906-911.
109. Parry BL, Udell C, Elliott JA, et al. Blunted phase-shift responses to morning bright light in premenstrual dysphoric disorder. J Biol Rhythms 1997; 12:443-456.
110. Lam RW, Carter D, Misri S, Kuan AJ, Yatham LN, Zis AP. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res 1999; 86:185-192.
111. Oprendek T, Parry B, Brown S. Differential reduction in symptoms of late luteal phase dysphoric disorder as a function of light therapy. J Womens Health 1994; 3:115-124.